Sensieva Test Menu

Insource Diagnostics

Women’s Health Panel

Worried about your health?





Insource Diagnostics

Leading Causes of Death for Women

 

The CDC estimates that between 10-40% of these deaths could be prevented. Lifestyle choices hold the key and the debate exists what they should be for each unique person. The power of diagnostic results can help monitor your health.


Reference: https://www.cdc.gov/women/lcod/2014/index.htm

Stop worrying
and take control.

Insource Diagnostics

 

 

InSource Diagnostics is proud to offer such a targeted healthcare panel dedicated to women and empowering them to take control of their health.

Tests Included

 

 

What is tested?


General Health Picture

  • Comprehensive Metabolic Panel
    • Organ Health
    • Diabetes Check
  • Complete Blood Count CBC
    • Anemia
    • Infection
    • Leukemia
  • Heart Health

Not feeling like yourself?

As we age, our bodies change and hormone levels change too. Feeling your best means your hormones need to be in balance. Getting tested will help you and your doctor discover what your body needs to be in balance.


Symptoms of hormone imbalance

  • Irregular or loss of menstruation
  • Hot flashes, sweating
  • Reduced sex drive
  • Changes in energy or mood
  • Reduction in breast tissue
  • Reduced bone density
  • Weight gain

Medication Related Hormone Changes

Medications like oral contraceptives and opioid therapy may contribute to hormone deficiency

As such, clinicians should consider the type of progestin in a patient's oral contraceptive formulation and the degree to which it may suppress or promote androgen production.

Testosterone is generally used under very limited circumstances in menopausal women and DHEA supplementation, although controversial in terms of efficacy, has been shown in some studies to counter the effects of low androgens in women with OPIAD or sex hormone deficiencies.4


Interfering Medications

  • Oral Contraceptives
  • Steroids
    (e.g., corticosterone, prednisone)
  • Pain Medication
    (e.g., opioids)
  • Antidepressants
    (e.g., Celexa, Cymbalta, Lexapro, Paxil, Prozac, Zoloft)
  • Benzodiazepines
    (e.g., xanax)
  • Beta blockers

 

Test Code: 6803

CPT: 85025;82728;82746;83540;83550;82607;85025;80053;80061 w/Reflex 83721;84443;84480;84439;84436;84479;86376;84702;82530;82627;82670;82677;83001;83002;84144;84146;82306
Tests Included CBC, CMP, Lipid,  Women's Hormone Panel
Patient Preparation Fasting
Sample Serum or Plasma & Whole Blood
Tube 2x Red, Green or Tiger Top & 1x Lavender
Test Turnaround Time 5 Days
Intended Patient Population 18+ and Older Adult Females
Limitations No Friday Collections
Shipping Requirements Overnight, Refrigerated
Specimen Stability 2 Days RF
Reject Criteria See Individual Component Test Requirements
Laboratory Developed Test (LDT) Yes
CMS Guidance NCD 190.15, NCD 190.18,
NCD 190.23, NCD 190.22,
LCD L36692

References

  1. K. Vincent, I. Tracey, Hormones and their Interaction with the Pain Experience, Rev Pain. 2008 Dec; 2(2): 20–24.
  2. Endocrine Society. "Testosterone therapy may help improve pain in men with low testosterone." ScienceDaily. ScienceDaily, 17 June 2013. <www.sciencedaily.com/releases/2013/06/130617142047.htm>
  3. T.W. Kragstrup, MD, Vitamin D supplementation for patients with chronic pain, Scand J Prim Health Care. 2011 Mar; 29(1): 4–5
  4. S. Colameco, MD, MEd; J. Coren, DO, MBA, Opioid-Induced Endocrinopathy, The Journal of the American Osteopathic Association, January 2009, Vol. 109, 20-25.
  5. M. Oettel and A. K. Mukhopadhyay, Progesterone: the forgotten hormone in men? The Aging Male 2004;7:236–257
  6. Cohen PG, The role of estradiol in the maintenance of secondary hypogonadism in males in erectile dysfunction. Med Hypotheses. 1998 Apr;50(4):331-3.
  7. E. E. Shipton and E. A. Shipton, Vitamin D Deficiency and Pain: Clinical Evidence of Low Levels of Vitamin D and Supplementation in Chronic Pain States, Pain Ther. 2015 Jun; 4(1): 67–87.
  8. Lerchbaum E1, Rabe T., Vitamin D and female fertility. Curr Opin Obstet Gynecol. 2014 Jun;26(3):145-50.